ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1924

Comparison of Proteomic Methods in Evaluating Biomarker-AKI Associations in Cardiac Surgery Patients

Session Information

Category: Pathology and Lab Medicine

  • 1600 Pathology and Lab Medicine

Authors

  • Liu, Richard Xiuri, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
  • Thiessen Philbrook, Heather, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
  • Ramachandran, Vasan S., Boston University School of Medicine, Boston, Massachusetts, United States
  • Coresh, Josef, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States
  • Ganz, Peter, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California, United States
  • Bonventre, Joseph V., Brigham and Women's Hospital, Boston, Massachusetts, United States
  • Kimmel, Paul L., National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, United States
  • Parikh, Chirag R., Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Background

Although immunoassays are the most widely used protein measurement method, aptamer-based methods such as the SomaScan platform can quantify up to 7,000 proteins per sample, creating new opportunities for unbiased discovery.

Methods

In a substudy of the TRIBE-AKI cohort, preop and postop plasma samples from 294 patients with previous immunoassay measurements were analyzed using the SomaScan platform. Inter-platform Spearman correlations (rs) and AKI associations were compared across 30 preop and 34 postop immunoassay-aptamer pairs. Possible factors contributing to inter-platform differences were tested for association with inter-platform correlation, including target protein, experimental, immunoassay, and aptamer characteristics.

Results

The median rs was 0.54 (IQR 0.34-0.83) in postop samples and 0.41 (IQR 0.21-0.69) in preop samples. We observed a strong association between rs and biomarker molarity, with Spearman correlation 0.64 preop and 0.53 postop. No strong associations with other factors were found, including %CVs of both platforms and storage time.
We observed significant immunoassay-AKI associations for 13 proteins preop and 24 postop, and SomaScan-AKI associations for 8 proteins preop and 12 postop. All significant AKI associations as measured by SomaScan were also significant as measured by immunoassay. AKI odds ratios were significantly different (P <0.05) between platforms in 4 (14%) pairs, none of which had rs >0.50.

Conclusion

Although similar AKI associations were observed overall, biomarkers with high physiological concentrations tended to have the best inter-platform operability. Aptamer assays provide unprecedented coverage, excellent precision, and promise for disease associations, but interpretation of results should keep in mind a broad range of correlations with immunoassays.

Funding

  • NIDDK Support